Medicenna Therapeutics Corp.
MDNA.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -468.11% | 15.59% | -16.13% | -34.01% | 108.02% |
| Total Depreciation and Amortization | -23.48% | -10.85% | 106.17% | 270.27% | 1,785.71% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 65.08% | -174.70% | 113.60% | -94.50% | -168.13% |
| Change in Net Operating Assets | 132.44% | -65.60% | 89.33% | 40.86% | 210.05% |
| Cash from Operations | 7.56% | -40.23% | 12.90% | -50.64% | 3.13% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -5.26% | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -100.00% | -99.75% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -9.09% | -101.00% | -102.67% | -99.82% | -- |
| Foreign Exchange rate Adjustments | 194.62% | -112.54% | 182.51% | -889.84% | -295.90% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 12.72% | -1,098.76% | 10.34% | -123.22% | -1.47% |